Sign in
TerminatedNo phase

Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion

Key facts

Who runs it
University Hospital Tuebingen
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
9 people enrolled
Started
28 Jul 2020
Ended
1 Mar 2024
Type of study
Interventional
Treatments tested
  • Lowering cholesterol concentrations by PCSK-9 inhibitor
Record updated
16 May 2024
Why it stopped
poor recruitment

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures
  • Medical indication for the treatment with a PCSK9-inhibitor
  • HbA1c < 6,5%

Who cannot take part

  • Diabetes mellitus
  • Any pancreatic disease
  • Hb < 11.5 g/dl (males) or Hb < 10.5 g/dl (females)
  • treatment with any medication that effects on blood glucose concentrations, e.g. antidiabetic drugs or steroids
  • Pregnant women or breastfeeding

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Dyslipidemia is characterized by low levels of HDLs, hypertriglyceridemia as well as an increases proportion of small dense LDLs. Changes in lipoprotein particles and its concentrations, especially increased levels of pro-atherogenic LDL particles play an important role in the development of cardiovascular diseases. It is well established that statin/PCSK9-inhibitor treatment is very effective in lowering LDL cholesterol levels and therefore in preventing cardiovascular events. Besides the beneficial effects on cardiovascular system, these therapies are unfortunately linked to increased risk for type 2 diabetes.

Read full original descriptionShow less

However underlying mechanisms for the association between LDL cholesterol levels and the risk for type 2 diabetes remains largely unknown.Type 2 diabetes is especially characterized by insulin resistance and impaired insulin secretion from pancreatic beta-cells. Insulin resistance alone is insufficient to cause type 2 diabetes, as long as the ß-cell is able to compensate for the increased demand for insulin. Once this compensatory mechanism reaches its physiological limits, individuals progress to type 2 diabetes. Accordingly we aimed to investigate the associations between LDL cholesterol concentrations and the key issue in the pathogenesis of type 2 diabetes, insulin secretion before and after lowering cholesterol concentration by treatment with Evolocumab for 12 weeks in patients with medical indication for a treatment with a PCSK9-inhibitor. Therefore, patients will either undergo a hyperglycemic clamp or a oral glucose tolerance test in randomized manner.

The group in the trial

  • LDL lowering therapyTreatment being tested

    Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.

    Treatment: Lowering cholesterol concentrations by PCSK-9 inhibitor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 May 2024